NO20071523L - Vaksiner - Google Patents

Vaksiner

Info

Publication number
NO20071523L
NO20071523L NO20071523A NO20071523A NO20071523L NO 20071523 L NO20071523 L NO 20071523L NO 20071523 A NO20071523 A NO 20071523A NO 20071523 A NO20071523 A NO 20071523A NO 20071523 L NO20071523 L NO 20071523L
Authority
NO
Norway
Prior art keywords
relates
malaria
vaccinations
immunize against
disease
Prior art date
Application number
NO20071523A
Other languages
English (en)
Inventor
Joseph D Cohen
Nadia Gabriela Tornieporth
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33306702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071523(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20071523L publication Critical patent/NO20071523L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse angår ny anvendelse av et malaria-antigen for å immunisere mot malaria-sykdom. Oppfinnelsen angår spesielt anvendelse av sporozoit-antigener, spesielt circumsporozoit- (CS) protein eller fragmenter derav, for å immunisere mot alvorlig malaria-sykdom.
NO20071523A 2004-09-16 2007-03-23 Vaksiner NO20071523L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0420634A GB0420634D0 (en) 2004-09-16 2004-09-16 Vaccines
PCT/EP2005/009995 WO2006029887A2 (en) 2004-09-16 2005-09-14 Vaccines comprising plasmodium antigens

Publications (1)

Publication Number Publication Date
NO20071523L true NO20071523L (no) 2007-03-28

Family

ID=33306702

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071523A NO20071523L (no) 2004-09-16 2007-03-23 Vaksiner

Country Status (18)

Country Link
US (1) US20080102091A1 (no)
EP (1) EP1791558A2 (no)
JP (2) JP5670611B2 (no)
KR (1) KR101362097B1 (no)
CN (2) CN101056653A (no)
AR (1) AR051023A1 (no)
AU (1) AU2005284223B2 (no)
BR (1) BRPI0515334A (no)
CA (1) CA2579527C (no)
GB (1) GB0420634D0 (no)
IL (1) IL181733A0 (no)
MA (1) MA28885B1 (no)
MX (1) MX2007003160A (no)
NO (1) NO20071523L (no)
RU (1) RU2423994C2 (no)
SG (2) SG159520A1 (no)
TW (1) TW200621287A (no)
WO (1) WO2006029887A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2794647B2 (ja) 1992-04-17 1998-09-10 株式会社間組 ダム構造とダムの築造法
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US9364525B2 (en) 2006-07-18 2016-06-14 Glaxosmithkline Biologicals Sa Vaccines for malaria
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
PL2137210T3 (pl) * 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
KR20100068390A (ko) * 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
WO2010108177A2 (en) * 2009-03-20 2010-09-23 University Of South Florida A method and composition using a dual specificity protein tyrosine phosphatase as an antimalarial drug target
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
BE1022174B1 (fr) * 2013-03-15 2016-02-24 Glaxosmithkline Biologicals S.A. Vaccin
GB201416773D0 (en) * 2014-09-23 2014-11-05 Glaxosmithkline Biolog S A And Chancellor Masters And Scolars Of The The University Of Oxford Novel Methods For Including An Imune Response
WO2016184784A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1
US9968665B2 (en) * 2015-09-16 2018-05-15 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
JP2022526334A (ja) 2019-03-25 2022-05-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新たなタウ種を標的化することによるタウオパチー障害の処置の方法
WO2020221451A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies binding to plasmodium circumsporozoite protein and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2927892A (en) * 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
CA2138997C (en) * 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
WO2002077195A2 (en) * 2001-03-26 2002-10-03 Walter Reed Army Institute Of Research Plasmodium falciparum ama-1 protein and uses thereof
WO2004044167A2 (en) * 2002-11-12 2004-05-27 Walter Reed Army Institute Of Research Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide
WO2005017157A1 (en) * 2003-08-15 2005-02-24 Commonwealth Scientific And Industrial Research Organisation (Csiro) Methods and means for altering fiber characteristics in fiber-producing plants

Also Published As

Publication number Publication date
BRPI0515334A (pt) 2008-07-22
SG159520A1 (en) 2010-03-30
CA2579527C (en) 2016-06-21
SG193159A1 (en) 2013-09-30
GB0420634D0 (en) 2004-10-20
KR101362097B1 (ko) 2014-02-21
MX2007003160A (es) 2007-10-23
MA28885B1 (fr) 2007-09-03
JP5670611B2 (ja) 2015-02-18
CN101056653A (zh) 2007-10-17
WO2006029887A2 (en) 2006-03-23
TW200621287A (en) 2006-07-01
WO2006029887A3 (en) 2006-05-11
AU2005284223A1 (en) 2006-03-23
JP5632404B2 (ja) 2014-11-26
EP1791558A2 (en) 2007-06-06
IL181733A0 (en) 2007-07-04
JP2012116849A (ja) 2012-06-21
US20080102091A1 (en) 2008-05-01
JP2008513400A (ja) 2008-05-01
CN104027795A (zh) 2014-09-10
KR20070052342A (ko) 2007-05-21
AR051023A1 (es) 2006-12-13
RU2007109608A (ru) 2008-10-27
AU2005284223B2 (en) 2011-12-15
CA2579527A1 (en) 2006-03-23
RU2423994C2 (ru) 2011-07-20

Similar Documents

Publication Publication Date Title
NO20071523L (no) Vaksiner
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
NO20072470L (no) Malariaigangsetter/forsterkervaksine
GB2434367A (en) Improved vaccines
DOP2010000056A (es) Un antigeno de malaria para vacunar contra la malaria
WO2004063963A3 (en) Novel proteins with altered immunogenicity
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2006036550A3 (en) Listeria-based and llo-based vaccines
CY1110157T1 (el) Χιμαιρικα ανασυνδυασμενα αντιγονα του toxoplasma gondii
EP2400021A3 (en) ErbB3 based methods and compositions for treating neoplasms
NO20090177L (no) Vaksiner for malaria
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
UA93508C2 (en) Anti-malaria vaccine
WO2006124712A3 (en) A method for improving the immunogenicity of plasmodium antigens
WO2007146359A3 (en) Sea lice antigen vaccines
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
MX2010007876A (es) Vectores virales recombinantes y composicion de vacuna para leishmaniasis.
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
WO2008009088A3 (en) Vaccine composition and immunization method
WO2007052238A8 (en) Chimeric antigens and vaccines
TH79424A (th) วัคซีน
DE602006010061D1 (de) Malariaimpfstoffe
WO2005007691A8 (en) East coast fever vaccine based on ctl-specific schizont antigens
Bartlett Furthering Promising Molecular Adjuvant Therapy Against Toxoplasma gondii
TH86422B (th) วัคซีน

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application